Cargando…

The Path to Paxlovid

Detalles Bibliográficos
Autor principal:	Halford, Bethany
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052793/ https://www.ncbi.nlm.nih.gov/pubmed/35505871 http://dx.doi.org/10.1021/acscentsci.2c00369

Ejemplares similares

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient
por: Shah, Aaisha, et al.
Publicado: (2022)

Paxlovid™ jetzt direkt an Patienten abgeben
por: Zimmermann, Gerd W.
Publicado: (2022)

Paxlovid-Induced Symptomatic Bradycardia and Syncope
por: Ganipisetti, Venu M, et al.
Publicado: (2023)

CARDIOGENIC SHOCK DUE TO PAXLOVID INTERACTION
por: Enstrom, Cate, et al.
Publicado: (2023)

Serotonin Syndrome Precipitated by Paxlovid Initiation
por: Nasser, Nicholas G, et al.
Publicado: (2023)

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
por: Marzi, Mahrokh, et al.
Publicado: (2022)

Carfilzomib Induced Microangiopathy due to Accumulation With Paxlovid
por: Philipponnet, Carole, et al.
Publicado: (2022)

Risks of paxlovid in a heart transplant recipient
por: Stawiarski, Kristin, et al.
Publicado: (2023)

A Rare Case of Paxlovid-Induced Pancreatitis
por: Zaidi, Syed Muhammad Hussain, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Computational prediction of interactions between Paxlovid and prescription drugs
por: Kim, Yeji, et al.
Publicado: (2023)

Paxlovid(TM) Information From FDA and Guidance for AES Members
por: Cokley, Jon A., et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

Projected COVID-19 Mortality Reduction From Paxlovid Rollout
por: Khunte, Mihir, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Paxlovid for hospitalized COVID-19 patients with chronic kidney disease
por: Cai, Hong, et al.
Publicado: (2023)

Activation of PXR causes drug interactions with Paxlovid in transgenic mice
por: Lei, Saifei, et al.
Publicado: (2023)

Pfizer, résultats très prometteurs de l’antiviral oral paxlovid
por: Manus, Jean-Marie
Publicado: (2022)

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
por: Pepperrell, Toby, et al.
Publicado: (2022)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2023)

Paxlovid-Bevorratung: Apotheker wollen jetzt Geld von den Praxen
por: Zimmermann, Gerd W.
Publicado: (2023)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China
por: Zhang, Weina, et al.
Publicado: (2023)

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
por: Periyasamy, P., et al.
Publicado: (2023)

Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics
por: Sagawa, Kazuko, et al.
Publicado: (2023)

DRUG INTERACTION BETWEEN PAXLOVID AND TACROLIMUS IN AN ADOLESCENT WITH INFLAMMATORY BOWEL DISEASE
por: Zaarur, Leenoy, et al.
Publicado: (2023)

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH
por: Mohamed, Sarah, et al.
Publicado: (2023)

The public health impact of Paxlovid COVID-19 treatment in the United States
por: Bai, Yuan, et al.
Publicado: (2023)

Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19
por: Cai, Hong, et al.
Publicado: (2022)

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
por: Sun, Fangfang, et al.
Publicado: (2022)

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022)

Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
por: Buxeraud, Jacques, et al.
Publicado: (2022)

Impact of Paxlovid on international normalized ratio among patients on chronic warfarin therapy
por: Muse, Oluwatoyosi, et al.
Publicado: (2022)

COVID-19: Therapie mit Paxlovid scheint auch für Schwangere sicher
por: Zink, Nicola
Publicado: (2023)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound
por: Ranard, Benjamin L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qjdkoaa4gtdjs2ofs4atu46l1c